
Conduit Bio is a digital platform that enhances drug discovery through multi-omics knowledge graphs and analytics. It allows biopharma teams to combine proprietary omics data with public sources, creating bespoke knowledge graphs and in silico models. The platform supports both wet and dry lab environments, enabling users to conduct simple queries or advanced machine learning analyses. With a no-code, collaborative software environment, Conduit Bio accelerates insights generation, improving target identification and biological understanding significantly. The company positions itself as a leader in the biopharma sector, providing tools that enhance the speed and accuracy of drug discovery processes.

Conduit Bio is a digital platform that enhances drug discovery through multi-omics knowledge graphs and analytics. It allows biopharma teams to combine proprietary omics data with public sources, creating bespoke knowledge graphs and in silico models. The platform supports both wet and dry lab environments, enabling users to conduct simple queries or advanced machine learning analyses. With a no-code, collaborative software environment, Conduit Bio accelerates insights generation, improving target identification and biological understanding significantly. The company positions itself as a leader in the biopharma sector, providing tools that enhance the speed and accuracy of drug discovery processes.
Sector: Biotechnology / Biopharma (drug discovery software)
Founded: 2021
HQ: London, United Kingdom
Stage: Pre-Seed
Notable investor: SFC Capital
Drug discovery / target identification and biological understanding
2021
Biotechnology
“SFC Capital participated in a Pre-Seed round”